We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation |

Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations

Miriam Potrony, MSc1; Joan Anton Puig-Butille, PhD2,3; Paula Aguilera, MD1,2; Celia Badenas, PhD2,3; Gemma Tell-Marti, MSc1,2; Cristina Carrera, MD, PhD1,2; Luis Javier del Pozo, MD4; Julian Conejo-Mir, MD5; Josep Malvehy, MD, PhD1,2; Susana Puig, MD, PhD1,2
[+] Author Affiliations
1Melanoma Unit, Dermatology Department, Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques d’August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
2Centro de Investigación Biomédica en Red en Enfermedades Raras, Valencia, Spain
3Melanoma Unit, Molecular Biology and Genetics Department, Hospital Clínic de Barcelona, Spain
4Department of Dermatology, Hospital Universitari Son Espases, Palma Mallorca, Spain
5Servicio de Dermatología del Hospital Universitario Virgen del Rocío, Sevilla, Spain
JAMA Dermatol. 2016;152(4):405-412. doi:10.1001/jamadermatol.2015.4356.
Text Size: A A A
Published online

Importance  The main high-penetrance melanoma susceptibility gene is CDKN2A, encoding p16INK4A and p14ARF. The gene MITF variant p.E318K also predisposes to melanoma and renal cell carcinoma. To date, the prevalence of MITF p.E318K and its clinical and phenotypical implications has not been previously assessed in a single cohort of Spanish patients with melanoma or in p16INK4A mutation carriers.

Objectives  To evaluate the prevalence of MITF p.E318K in Spanish patients with melanoma and assess the association with clinical and phenotypic features.

Design, Setting, and Participants  A hospital-based, case-control study was conducted at the Melanoma Unit of Hospital Clinic of Barcelona, with MITF p.E318K genotyped in all patients using TaqMan probes. We included 531 patients: 271 patients with multiple primary melanoma (MPM) without mutations affecting p16INK4A (wild-type p16INK4A); 191 probands from melanoma-prone families with a single melanoma diagnosis and without mutations affecting p16INK4A, and 69 probands from different families carrying CDKN2A mutations affecting p16INK4A. A population-based series of 499 age- and sex-matched cancer-free individuals from the Spanish National Bank of DNA were included as controls. Patients were recruited between January 1, 1992, and June 30, 2014; data analysis was conducted from September 1 to November 30, 2014.

Main Outcomes and Measures  The genetic results of the MITF p.E318K variant were correlated with clinical and phenotypic features.

Results  Among the 531 patients, the prevalence of the MITF p.E318K variant was calculated among the different subsets of patients included and was 1.9% (9 of 462) in all melanoma patients with wild-type p16INK4A, 2.6% (7 of 271) in those with MPM, and 2.9% (2 of 69) in the probands of families with p16INK4A mutations. With results reported as odds ratio (95% CI), the MITF p.E318K was associated with an increased melanoma risk (3.3 [1.43-7.43]; P < .01), especially in MPM (4.5 [1.83-11.01]; P < .01) and high nevi count (>200 nevi) (8.4 [2.14-33.19]; P < .01). Two fast-growing melanomas were detected among 2 MITF p.E318K carriers during dermatologic digital follow-up.

Conclusions and Relevance  In addition to melanoma risk, MITF p.E318K is associated with a high nevi count and could play a role in fast-growing melanomas. Testing for MITF p.E318K should not exclude patients with known mutations in p16INK4A. Strict dermatologic surveillance, periodic self-examination, and renal cell carcinoma surveillance should be encouraged in this context.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?


Place holder to copy figure label and caption
Figure 1.

A fast-growing melanoma developed within 3 weeks and was the fourth to occur in patient M0881-01. Clinical picture of a 4-mm-diameter nodular lesion located on the elbow (A); dermoscopic image of the lesion showing hypopigmentation, asymmetry, unspecific pattern, atypical vessels, and blue-whitish veil (B). Under confocal microscopy, the lesion shows an ulcerated central area (C) with atypical nests in upper dermis with bright roundish nucleated cells in noncohesive nests (D). Histopathologic examination shows an ulcerated nodular melanoma (hematoxylin-eosin, original magnification ×2) (E) and nests of atypical cells and presence of mitosis (hematoxylin-eosin, original magnification ×10) (F).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

The back of patient M3879-01 with 2 previous melanomas and more than 200 nevi. Six dermoscopic images show the predominant pattern, reticulated dark brown.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles